As the scope of this study is limited to identifying the most potent combination treatment for improving the efficacy of IACS in BRAFi-resistant melanomas and testing their metabolic/molecular correlates of efficacy, we did not perform functional genetics analysis to tease out specific molecular players, for example PGC1α, as a potential causal factor of FA dependence in BRAFi-resistant melanomas. This evidence concerns the gene PPARGC1A and melanoma.